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Abstract As systemic cancer therapies improve and are
able to control metastatic disease outside the central nervous
system, the brain is increasingly the first site of relapse. The
blood–brain barrier (BBB) represents a major challenge to
the delivery of therapeutics to the brain. Macrophages orig-
inating from circulating monocytes are able to infiltrate
brain metastases while the BBB is intact. Here, we show
that this ability can be exploited to deliver both diagnostic
and therapeutic nanoparticles specifically to experimental
brain metastases of breast cancer.
Keywords Breast cancer . Brain metastasis . Gold-silica
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1 Introduction
Brain metastases are a significant clinical challenge. They are
diagnosed in 100,000–170,000 patients/year in the United
States (Posner 1992; Weil et al. 2005) and outnumber primary
brain tumors by a ratio of 10 to 1 (Cairncross and Posner 1983;
Walker et al. 1985;Posner 1992).Theyare estimated tooccur in
20–40 % of all cancer patients (Cairncross and Posner 1983;
Posner 1995). The incidence rate of brainmetastasis is thought
to be increasing as a function of the aging population, better
treatment of non-central nervous system (CNS) disease and
improved imaging techniques. The most common primary
tumor sites are lung (40–50 %), breast (13–17 %), melanoma
(11–17 %), renal (6–16 %), and GI tract (4–6 %) (Barnholtz-
Sloan et al. 2004; Klos and O’Neill 2004). At least 10 % of
patientswith primary small cell lung cancer (SCLC) have brain
metastasis at diagnosis (Hochstenbag et al. 2000; Grossi et al.
2001), however amore recent prospective study of432patients
in theNetherlands found the rate to be 18% (Seute et al. 2004).
Patientswith locally advancednon-small cell lung cancer are at
thehighest riskforbrainmetastasis,withsomestudies reporting
greater than 50% of patients developing brain metastasis over
the course of the disease (Stuschke et al. 1999).
Breast cancer metastatic to the brain is most prevalent in
the triple negative (Lin et al. 2008) and HER2+ subpopula-
tions (Bendell et al. 2003; Clayton et al. 2004; Lin and
Winer 2007; Stemmler et al. 2006; Yau et al. 2006), where
the median survival time ranges from 2 to 16 months and the
mean 1-year survival is ~20 % (Mahmoud-Ahmed AS
2002). Since targeted therapies against HER2+ disease are
able to successfully control non-CNS disease, the brain is
increasingly being seen as the first site of relapse (Burstein
et al. 2005). Currently, the mainstays of treatment for meta-
static brain tumors are whole brain radiation therapy
(WBRT), surgery, stereotactic radiosurgery or a combina-
tion of these modalities. However, significant neurotoxicity
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has been reported with the use of WBRT, resulting in endo-
crine dysfunction, significant memory loss and dementia
(Sneed et al. 1999; Patchell and Regine 2003; Lo et al. 2005).
Drug uptake into the brain is limited by numerous factors,
including physical barriers such as the blood–brain barrier
(BBB) and the blood–cerebrospinal fluid (blood–CSF) barrier,
andasubstrate’saffinityforspecific transport systems locatedat
both of these interfaces (Graff and Pollack 2004; Pardridge
2005). Despite recent indications that chemical modulation of
the BBB may be feasible (Carman et al. 2011), under physio-
logical conditions, drugs and other substances can enter the
brain only by passive transcellular diffusion, receptor-
mediated transcytosis, or through the action of specific carrier
systems. While in general, the more lipid-soluble a molecule
is, the more readily it will penetrate the BBB and blood–CSF
barrier to reach targets in the CNS, many lipid-soluble thera-
peutics have much lower brain permeability than would be
predicted on the basis of their solubility (Begley 2004;
Muldoon et al. 2007). In an experimental model of brain
metastases of breast cancer, cytotoxic concentrations of pac-
litaxel were reached only in a subset (<10 %) of the “leakiest”
metastases (Lockman et al. 2010), and this therapy was unable
to reduce the metastatic burden in the brain over the period of
the study. All of these factors render the brain a “sanctuary”
site for metastases.
More than two decades ago, Fidler and colleagues provided
evidence thatmacrophages of bloodmonocyte origin can infil-
trate experimental brain metastases while the blood–brain bar-
rier is intact (Schackert et al. 1988). Even earlier, Morantz and
colleagues had quantified the content of macrophages in clini-
cal specimens (Morantz et al. 1979). They examined 12metas-
tases to the brain from a variety of primary tumors. The mean
contentofmacrophageswas24%witha rangeof4 to70%.The
specific means by which macrophages are recruited to the
metastasis is largely unknown. Primary brain tumors such as
gliomas produce MCP1 and HGF/SF1, which attract mono-
cytes (Strik et al. 2004). Whether there are similar immuno-
modulatory cytokines and chemokines elaborated by
intracranial metastases has been “poorly investigated to date”
(Strik et al. 2004).
The use of monocyte/macrophages as delivery vehicles to
the CNS has been investigated in situations other than
malignancy. Afergan et al. demonstrated the delivery of
serotonin to the brain by monocytes, which had phagocy-
tosed nano-liposomes containing this otherwise brain imper-
meant drug (Afergan et al. 2008). Dou and colleagues
utilized bone marrow derived macrophages as carriers of
and depots for antiretroviral drugs to treat and attenuate the
symptoms of HIV-associated neurocognitive disorder (Dou et
al. 2009). Therefore, we hypothesized that nanoparticle-laden
monocytes/macrophages would home in to intracranial meta-
static deposits by crossing the blood–brain barrier following
injection into the systemic circulation. If successful, this
would open the door to the use of monocytes/macrophages
for the delivery of therapeutic nanovectors as well as nano-
formulated therapeutics to malignant intracranial lesions.
2 Materials and methods
2.1 Fabrication of gold (Au) nanoshells
Au nanoshells (NS) [r1, r2]0[66, 80]nm were fabricated by
seed mediated electroless plating of Au onto silica spheres as
previously reported (Oldenburg et al. 1998; Brinson et al.
2008). Briefly, monodisperse silica nanospheres of 66±2 nm
radii were synthesized by the hydrolysis of tetraethylorthosili-
cate (TEOS) inbasicsolutionvia theStoebermethod(Stoeberet
al. 1968). The silica particles are redispersed in ethanol and
functionalized with (3-aminopropyl) triethoxysilane (APTES,
Sigma) overnight. These amine-terminated silica nanospheres
werewashed twice to remove excess amines and redispersed in
ethanol. Theprecursor nanoparticleswere preparedbydecorat-
ing the silica particles with small gold colloid (2–3 nm) fabri-
cated by the method reported by Duff et al. (1993). The
precursor particles were left unperturbed for 24 h at room
temperature, following which they were washed and redis-
persed in H2O (10 mL). A plating solution was prepared in an
amber bottle by mixing potassium carbonate (anhydrous,
Fisher, Fairlawn, NJ) with 1 % HAuCl4 solution in H2O
(200 mL). The plating solution was aged for 48 h before using
it tofabricate thenanoshells.Acontinuousgoldshellwasgrown
around the silica nanospheres by mixing the plating solution
with different aliquots of the precursor particles and bubbling
CO(g) for 10 s (Brinson et al. 2008). The reactionwas scaled up
to obtain the appropriate volume of nanoshells; the nanoshells
were washed twice and finally redispersed in H2O.
2.2 Isolation of Monocytes from Buffy Coat
Human whole blood was obtained from the Indiana Blood
Center (Indianapolis, IN) for the isolation of monocytes.
Lymphocytes, monocytes, and platelets, i.e., the buffy coat,
were isolated using Ficoll (GE Healthcare Biosciences,
Piscataway, NJ) density gradient centrifugation. Monocytes
were separated from the other components of the buffy coat
using MicroBeads conjugated to monoclonal mouse anti-
human CD14 antibodies and MACS® cell separation system
(Miltenyi Biotec, Auburn, CA).
2.3 Imaging of gold-silica nanoshells loaded in monocytes/
macrophages
Five thousand monocytes/macrophages were incubated in
200 μl RPMI media supplemented with M-CSF with 8.3×
108 nanoshells for 3 days at 37 °C, 5%CO2. The visualization
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was performed using a Bio-Rad Radiance 2100 MP Rainbow
Confocal/Multiphoton System. The images were acquired
using the ×10 objective.
2.4 Imaging of red fluorescence microspheres loaded
in monocytes/macrophages
Specimens for confocal fluorescence microscopy were pre-
pared by pipetting 50 μL of the red fluorescently labeled
microsphere suspension (FluoSpheres® NeutrAvidin® la-
beled microspheres; 0.04 μm; red fluorescent, excitation
580 nm, emission 605 nm; Molecular Probes, Invitrogen,
Carlsbad, CA) onto the glass bottom of 35 mm glass bottom
dishes (MatTek Corporation, Ashland, MA). The dishes
were left at room temperature for 30 min to allow time for
the particles to settle. Three thousand macrophages sus-
pended in 100 μL of RPMI media were added to the glass
bottom and the dishes were incubated at 37 °C for 1 h to
allow the cells to attach. Three milliliters of RPMI supple-
mented with M-CSF was added to the cells and they were
incubated for 3 days at 37 °C, 5 % CO2.
2.5 Imaging of gold nanospheres and red fluorescence
microspheres loaded in monocytes/macrophages
Electron microscopy specimens were prepared by adding
50 μL of the red fluorescently labeled microsphere suspen-
sion to a Thermanox coverslip [cut in half], which was
placed in a 35 mm tissue culture dish. 50 μL of gold
streptavidin conjugate, 20 nm were added to the same cov-
erslip followed by 300,000 macrophages in 100 μL of
media. Dishes were incubated at 37 °C for 1 h in order for
the cells to attach. Three milliliters of RPMI supplemented
with M-CSF was added to the dish and the dishes were
incubated for 3 days at 37 °C, 5 % CO2. Cells were then
fixed in 2 % paraformaldehyde, 2 % glutaraldehyde in
0.1 M PO4 buffer.
2.6 Establishment of the brain metastatic tumor xenografts
The human MDA-MB-231 BR “brain-seeking” (231-BR)
cell line expressing enhanced green fluorescent protein
(eGFP) was produced and kindly provided by Dr. Patricia
S Steeg (National Cancer Institute, Bethesda, MD). The
cells were maintained in RPMI1640 (Cellgro, Mediatech,
Inc., Manassas, VA) supplemented with 10 % fetal bovine
serum (Gibco, Invitrogen, Grand Island, NY) and 1 % anti-
biotic–antimycotic (Invitrogen, Carlsbad, CA). Cells were
kept in a humidified atmosphere with 5 % CO2 at 37 °C.
eGFP expression in the cells was confirmed by fluorescent
microscopy. Prior to beginning, the study protocol was
approved by the Institutional Animal Care and Use
Committee of the Indiana University School of Medicine.
All experiments were conducted in accordance with the NIH
guidelines for the care and use of laboratory animals. Six- to
eight-week-old athymic nu/nu female mice (Harlan
Sprague–Dawley Inc., Indianapolis, IN) were used to estab-
lish human breast metastatic tumor xenografts in the brain.
A cell suspension of eGFP expressing 231-BR cell line (231-
BR-eGFP) in the exponential growth phase was prepared in a
concentration of 250,000 cells in 100 μl HBSS. Under iso-
flurane anesthesia, the cells were inoculated into the left
cardiac ventricle of three mice. After 4 weeks, the mice
evidenced symptoms of brain metastasis, e.g., hind limb pa-
ralysis. Mice were sacrificed; brains were removed and fixed
in 10 % buffered formalin (Protocol™, Fisher Scientific,
Kalamazoo, MI). Following paraffin-embedding, 5-μm sec-
tions were cut and the sections viewed using an Olympus
BX41 fluorescence microscope fitted with a ×40 FITC filter.
A second group of 12 mice underwent intracardiac injec-
tion with the 231-BR-eGFP cells as above. Upon evidence
of cerebral metastasis, monocytes were isolated and loaded
with red fluorescent microspheres as follows: 20.8×107
monocytes in 25 mL of RPMI media (Cellgro, Mediatech,
Inc., Manassas, VA) supplemented with 10 % fetal bovine
Fig. 1 Phagocytosis of gold-
silica nanoshells by macro-
phages. Photomicrographs of
transmitted light images of
macrophages (control) (a) and
following 3 days incubation
with nanoshells (b). The visu-
alization was performed using a
Bio-Rad Radiance 2100 MP
Rainbow Confocal/Multiphoton
System. The images were ac-
quired using the ×10 objective
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serum (Gibco, Invitrogen, Grand Island, NY) and 1 % anti-
biotic–antimycotic (Invitrogen, Carlsbad, CA) were incubat-
ed with 50 μ l of red fluorescent FluoSpheres®
NeutrAvidin®-labeled microspheres (0.04 μm; excitation
580 nm, emission 605 nm; Molecular Probes, Invitrogen,
Carlsbad, CA) in a VueLife® FEP cell culture bag
(American Fluoroseal Corporation, Gaithersburg, MD)
overnight at 37 °C, 5 % CO2. To remove any unphagocy-
tosed red fluorescent microspheres, cells were washed with
PBS twice followed by centrifugation. A total of 4.1×107
cells were collected. The presence of the red fluorescent
microspheres in the cells was confirmed by fluorescence
microscopy. The cell concentration was adjusted to 107/
100 μl by adding 410 μl PBS to the cell pellet. One hundred
microliters of the cell suspension was injected into the
systemic circulation via the tail vein; 24 h after injection
of the monocytes/macrophages, the mice were euthanized.
2.7 Biodistribution analysis of mouse organs
following injection of monocytes/macrophages loaded
with red fluorescent microspheres
Following the systemic injection of monocytes/macrophages
containing the fluorescently labeled microspheres, mice were
sacrificedand thebrain, lung, liver, and theheartweredissected.
The presence and location of metastatic tumor foci (green
fluorescence) and monocytes/macrophages loaded with the
red fluorescent microspheres in these organs was determined
using an optical imaging system, Berthold NightOwl Optical
Imager (Berthold Technologies, Oak Ridge, TN) loaded with
Berthold Winlight 32 software (Berthold Technologies). The
images of green fluorescence and red fluorescence were taken
after exposure times of 100 and 500 ms, respectively. The
intensity of the fluorescence in different area of the organs
was measured using the signal intensity bar.
Fig. 2 Cellular uptake of gold-silica nanoshells and red fluorescent
microspheres by monocytes/macrophages. a Transmission electron mi-
crograph of monocytes/macrophages incubated with nanoparticles
reveals intracellular localization of gold conjugates (arrow 1 in inset) as
well as the ingested red fluorescent microspheres located in the vacuoles
in the cytoplasm (arrow 2 in inset). b Fluorescence microscopy imaging
shows significant intensity of red fluorescence (580/605 nm) indicating
the presence of intracellular red fluorescent microspheres
Fig. 3 Ex vivo images of whole brain of mice injected with mono-
cytes/macrophages loaded with red fluorescent microspheres. The
presence and location of metastatic brain tumor foci (green fluores-
cence) and macrophages loaded with the red fluorescent microspheres
was determined after resection using an optical imaging system. The
images of green fluorescence (green fluorescent protein, gfp) and red
fluorescence (red fluorescent particles, rfp) were taken after exposure
times of 100 and 500 ms, respectively. The intensity of the fluores-
cence in different area of the brain is measured using the signal
intensity bar. Values are normalized relative to the exposure times
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2.8 Immunofluorescence analysis of monocytes/macrophages
in the green fluorescent brain metastatic tumor cells
After imaging, brains were bisected along the sagittal plane,
and fixed by perfusion in 4 % paraformaldehyde overnight
at 4 °C. For further fixation the brain hemispheres were
transferred to 20 % sucrose solution and fixed overnight at
4 °C. The fixed brain was frozen in Tissue-Tek O.C.T.
compound (Sakura Finetec, Torrance, CA). Brains were
sectioned serially in 5-μm increments, processed for immu-
nofluorescent staining and imaging. eGFP expressing tumor
cells in brain metastases and red fluorescent microspheres
were detected by confocal microscopy using Olympus
FV1000 MPE (Olympus, Center Valley, PA). In order to
determine if the red fluorescent microspheres were
contained within human monocytes/macrophages, brain
Fig. 4 Histologic images of
brain metastatic tumor cells. a
Paraffin-embedded section of
the brain of a control mouse
showing the formation of
metastatic brain lesions derived
from eGFP expressing breast
cancer cells. b Macrophages
loaded with red fluorescent
nanospheres infiltrating the
brain metastases detected by
immunofluorescent staining us-
ing anti-human CD68 antibod-
ies labeled with APEX Pacific
Blue fluorochrome. Green fluo-
rescence is emitted by the brain
metastatic tumor cells. Red
fluorescence and blue fluores-
cence result from the red fluo-
rescent nanospheres included
within the macrophages and the
macrophage staining,
respectively
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sections were stained with anti-human CD68 antibodies
(clone C-18; Santa Cruz Biotechnology, Santa Cruz, CA)
labeled with APEX Pacific Blue fluorochrome. The labeling
of the antibodies was performed using APEX Pacific Blue™
Antibody labeling Kit (Molecular Probes, Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruction.
3 Results and discussion
This study was designed as a pilot to test whether loaded
monocytes/macrophages are able to maneuver around the
BBB and actively deliver nanoparticles to intracranial me-
tastasis with the potential, to be realized, to deliver effective
therapy. In a previous publication, the efficient phagocytosis
of gold nanoshells by monocytes/macrophages was demon-
strated (Choi et al. 2007). Phagocytosis of nanoshells is so
avid, in fact, that the monocytes/macrophages are rendered
black in optical imaging (Fig. 1). This appears to occur with-
out exception in every monocyte/macrophage in culture.
To detect the presence of the nanoparticle-laden macro-
phages in the brain, fluorescently labeled microspheres were
used to track macrophage location. Although fluorescent
nanoshells have been demonstrated that combine both diag-
nostic and therapeutic functions in the same nanoparticle,
(Bardhan et al. 2008, 2009a, 2009b; Tam et al. 2007) here
we chose to investigate delivery by a “cocktail” of two
different types of nanoparticles, one therapeutic and one
contrast agent. Prior to commencing the in vivo experiment,
it was determined if monocytes would phagocytose the
fluorescently labeled microspheres as avidly as gold nano-
shells. Avid uptake of the fluorescently labeled micro-
spheres was observed, as shown in Fig. 2. Although it
appears from this two-dimensional photomicrograph that
the uptake is within the nucleus, with three-dimensional
imaging it can be observed that the microspheres are peri-
nuclear, which is confirmed by transmission electron mi-
croscopy (TEM) imaging. The TEM image also shows a
much larger number of microspheres phagocytosed in rela-
tion to the numbers of gold conjugate. As with the phago-
cytosis of the nanoshells, the phagocytosis of the
microspheres and gold conjugates appears to be robust in
every monocyte/macrophage exposed to the nanoparticles.
To test the hypothesis that systemically injected,
nanoparticle-laden monocytes/macrophages would home in
to intracranial metastatic deposits by crossing the blood–
brain barrier a mouse model of breast cancer metastatic to
the brain, the human MDA-MB-231 BR “brain-seeking”
(231-BR) cell lines expressing enhanced green fluorescent
protein (eGFP), was utilized (Yoneda et al. 2001; Palmieri et
al. 2007). Twelve mice underwent intracardiac injection of
the 231-BR cells of which three died following injection.
The remaining nine mice underwent tail vein injection of the
nano-laden macrophages; at necropsy it was determined that
six of these nine mice had actually developed brain metas-
tasis, three had not. Imaging of the freshly dissected brains
of mice injected 24 h earlier with the loaded macrophages
reveals that the green [metastasis] and red [microspheres]
fluorescence overlap each other with maximal intensity in a
posterior direction (Fig. 3). This suggests that the micro-
spheres have been successfully delivered to the metastases.
Confocal microscopy of the brain sections reveals eGFP
expressing tumor cells forming brain metastases (Fig. 4a). Red
fluorescence from the microspheres was observed within the
metastases of two of the six mice with brain metastases. To
determine if the red fluorescent microspheres were contained
within human macrophages, brain sections were stained with
anti-human CD68 antibodies labeled with APEX Pacific Blue
fluorochrome. As observable in Fig. 4b, the microspheres are
containedwith the macrophages, which are intercalatedwithin
Fig. 5 Biodistribution images of mouse organs following injection of
monocytes/macrophages loaded with red fluorescent nanospheres. The
distribution of metastatic tumor foci (green fluorescence) and macro-
phages loaded with the red fluorescent nanospheres in the brain, lung,
liver, and the heart was determined after resection using an optical
imaging system. The images of green fluorescence (green fluorescent
protein, gfp) and red fluorescence (red fluorescent particles, rfp) were
taken after exposure time of 600 ms. The intensity of the fluorescence
in different area of the organs is measured using the signal intensity
bar. There is abundant uptake of microsphere-laden macrophages in the
liver. Brain metastases are located in the left hemisphere of the brain.
The distribution of the red fluorescence within the brain overlaps that
of the green fluorescence suggesting that the microsphere-laden macro-
phages are co-located with the cerebral metastases
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the metastases. Tail vein injection in athymic nu/nu mice is
technically challenging given the small size of this vessel. In
the four mice for which no delivery of nanoparticles is ob-
served, the hypothesis is that the needle transversed the vein
and the macrophage suspension infiltrated the subcutaneous
tissue surrounding the tail vein rather than entering it and the
systemic circulation.
Whole-body fluorescence imaging of mice following the
systemic injection of macrophages containing the fluores-
cently labeled microspheres shows an initial [within
minutes] and temporary residence in the lungs followed by
residence in the liver and spleen which occurs over hours to
days (Fig. 5 and data not shown).
Our work is focused on the treatment of metastases from
breast cancer. This is a critical unmet clinical need.Thepurpose
our study was to test the hypothesis that nanoparticle-laden
monocytes/macrophages would home in to intracranial meta-
static deposits by crossing the blood–brain barrier following
injection into the systemic circulation. The activated macro-
phages not only cross the BBB but as shown in Fig. 3, they
envelop the metastatic cells delivering the loaded nanoparticle
to less than a cell width away from the nearest metastatic cell.
This “Trojan Horse” delivery method has been designed to
address the challenges to successful cancer nanotherapeutics
posedby the tumormicroenvironment. It takes advantageof the
recruitment of macrophages to the metastatic lesions; this is
active transport of the nanovectors likely the result of the
productions of chemoattractant(s) by the metastasis, which
does not require the Enhanced Permeability and Retention
effect or diffusion of the nanovector.
Injection of monocytes/macrophages into the systemic
circulation resulted in residence in the liver and lungs as
well as transport to the brain metastasis. This result was
predictable. Previous studies have demonstrated that when
marrow derived mononuclear cells or peritoneal macro-
phages are injected into the systemic circulation they home
to the same tissues and have a distribution similar to endog-
enous macrophages (Kennedy and Abkowitz 1998; Freeman
et al. 1999). This distribution is to treatment advantage.
Monocyte/macrophages as deliveryvehicles can beenvisioned
as a pan-metastatic treatment because, in addition to the brain,
the lungs and liver are frequent sites ofmetastatic disease.What
is unknown and to be determined in follow-on studies is the
exact percentage of the administered dose that actually crosses
the BBB. Also to be determined is the rate at which the macro-
phage will discharge its cargo and whether or not it will be
necessary to destroy the macrophage for this to happen.
4 Conclusions
To our knowledge, we report the first successful demonstra-
tion of the active delivery, usingmacrophages, of nanoparticles
to brainmetastases and it paves the way for testing thismethod
to deliver other nanovectors including nanorods, hollow nano-
spheres in the sub-100- and sub-50 nm range as well as nano-
formulated therapeutics.
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